Io Biotech

Io Biotech company information, Employees & Contact Information

Explore related pages

Related company profiles:

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. IO Biotech has an experienced management team within the immune-oncology field and a world-class advisory board.

Company Details

Employees
94
Founded
-
Address
Ole Maaloesvej 3, Copenhagen,denmark 2200,denmark
Phone
(452)194-7856
Email
mz****@****ech.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Copenhagen, Denmark
Looking for a particular Io Biotech employee's phone or email?

Io Biotech Questions

News

IO Biotech Announces Participation in Upcoming Investor Conferences - Yahoo Finance

IO Biotech Announces Participation in Upcoming Investor Conferences Yahoo Finance

19.4‑Month mPFS: IO Biotech Cylembio+KEYTRUDA Shows Subgroup Benefits, No Added Systemic Toxicity - Stock Titan

19.4‑Month mPFS: IO Biotech Cylembio+KEYTRUDA Shows Subgroup Benefits, No Added Systemic Toxicity Stock Titan

IO Biotech Faces FDA Setback with Cylembio; Plans New Study and Workforce Restructuring - Quiver Quantitative

IO Biotech Faces FDA Setback with Cylembio; Plans New Study and Workforce Restructuring Quiver Quantitative

IO Biotech's Co-Founder Mads Hald Andersen Highlights Advances in Cancer Vaccine Research at 2025 AACR Annual Meeting - Nasdaq

IO Biotech's Co-Founder Mads Hald Andersen Highlights Advances in Cancer Vaccine Research at 2025 AACR Annual Meeting Nasdaq

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - Yahoo Finance

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma Yahoo Finance

FDA Recommends Against Cancer Vaccine BLA: IO Biotech's Cylembio Faces Setback, 50% Staff Cut - Stock Titan

FDA Recommends Against Cancer Vaccine BLA: IO Biotech's Cylembio Faces Setback, 50% Staff Cut Stock Titan

IO Biotech Announces Upcoming Investor Conferences and Corporate Update on Cylembio® Development - Quiver Quantitative

IO Biotech Announces Upcoming Investor Conferences and Corporate Update on Cylembio® Development Quiver Quantitative

IO Biotech Publishes Preclinical Results for IO112 Cancer Vaccine, IND Submission Expected in 2025 - Nasdaq

IO Biotech Publishes Preclinical Results for IO112 Cancer Vaccine, IND Submission Expected in 2025 Nasdaq

Cancer Vaccine Developer IO Biotech to Present Latest Corporate Updates at Global Healthcare Forums - Stock Titan

Cancer Vaccine Developer IO Biotech to Present Latest Corporate Updates at Global Healthcare Forums Stock Titan

IO Biotech to Present Phase 3 and Phase 2 Trial Results of IO102-IO103 Cancer Vaccine at ESMO 2025 Congress - Quiver Quantitative

IO Biotech to Present Phase 3 and Phase 2 Trial Results of IO102-IO103 Cancer Vaccine at ESMO 2025 Congress Quiver Quantitative

IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference - Nasdaq

IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference Nasdaq

Major Phase 3 Results Coming: IO Biotech's Novel Melanoma Treatment Could Challenge Standard of Care - Stock Titan

Major Phase 3 Results Coming: IO Biotech's Novel Melanoma Treatment Could Challenge Standard of Care Stock Titan

IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans - Nasdaq

IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans Nasdaq

IO Biotech's Melanoma Vaccine Trial Falls Short of Statistical Goals Despite Clinical Benefits - Stock Titan

IO Biotech's Melanoma Vaccine Trial Falls Short of Statistical Goals Despite Clinical Benefits Stock Titan

IO Biotech to Present Cylembio™ Development Update at 45th Annual Cowen Health Care Conference - Quiver Quantitative

IO Biotech to Present Cylembio™ Development Update at 45th Annual Cowen Health Care Conference Quiver Quantitative

Clinical Trial Results: IO Biotech's Melanoma Drug Nearly Doubles Survival Time vs Standard Treatment - Stock Titan

Clinical Trial Results: IO Biotech's Melanoma Drug Nearly Doubles Survival Time vs Standard Treatment Stock Titan

Late-Breaking Cancer Vaccine Results: IO Biotech's Phase 3 Melanoma Trial Gets Coveted ESMO Spotlight - Stock Titan

Late-Breaking Cancer Vaccine Results: IO Biotech's Phase 3 Melanoma Trial Gets Coveted ESMO Spotlight Stock Titan

Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough - Stock Titan

Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough Stock Titan

Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 - Stock Titan

Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 Stock Titan

After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine - The American Journal of Managed Care® (AJMC®)

After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine The American Journal of Managed Care® (AJMC®)

IO Biotech to pursue cancer vaccine approval despite Phase III miss - Clinical Trials Arena

IO Biotech to pursue cancer vaccine approval despite Phase III miss Clinical Trials Arena

ESMO 2025 preview – IO Biotech's hollow victory | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2025 preview – IO Biotech's hollow victory | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

IO Biotech Reports Promising Phase 3 Trial Results for Cylembio® in Combination with Pembrolizumab in Advanced Melanoma - Quiver Quantitative

IO Biotech Reports Promising Phase 3 Trial Results for Cylembio® in Combination with Pembrolizumab in Advanced Melanoma Quiver Quantitative

IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters

IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal Reuters

FDA Recommends Against Immediate BLA Filing for Melanoma Vaccine Candidate - Dermatology Times

FDA Recommends Against Immediate BLA Filing for Melanoma Vaccine Candidate Dermatology Times

IO102-IO103 Plus Pembrolizumab Shows Promise in Treatment-Naïve, Advanced Solid Tumors - Targeted Oncology

IO102-IO103 Plus Pembrolizumab Shows Promise in Treatment-Naïve, Advanced Solid Tumors Targeted Oncology

IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive

IO Biotech sees path forward for skin cancer vaccine despite study setback BioPharma Dive

IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans - Quiver Quantitative

IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans Quiver Quantitative

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial - Vaccine Advisor

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial Vaccine Advisor

IO Biotech Appoints Marjan Shamsaei, PharmD as SVP - citybiz

IO Biotech Appoints Marjan Shamsaei, PharmD as SVP citybiz

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer - citybiz

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer citybiz

Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma - OncLive

Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma OncLive

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? Yahoo Finance

IO Biotech's cancer vaccine Cylembio falls short in Phase III melanoma trial - FirstWord Pharma

IO Biotech's cancer vaccine Cylembio falls short in Phase III melanoma trial FirstWord Pharma

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma Seeking Alpha

IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval - European Biotechnology Magazine

IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval European Biotechnology Magazine

FDA rejection prompts IO Biotech to cut workforce by 50% - medwatch.com

FDA rejection prompts IO Biotech to cut workforce by 50% medwatch.com

IO Biotech - Fierce Biotech

IO Biotech Fierce Biotech

Nvidia Had a $900 MILLION Bet on CoreWeave in Q1. How Should You Play CRWV Stock Here? - The Globe and Mail

Nvidia Had a $900 MILLION Bet on CoreWeave in Q1. How Should You Play CRWV Stock Here? The Globe and Mail

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x - Stocktwits

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x Stocktwits

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer - PR Newswire

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer PR Newswire

IO Biotech: A Phase 3 Company Getting No Respect (NASDAQ:IOBT) - Seeking Alpha

IO Biotech: A Phase 3 Company Getting No Respect (NASDAQ:IOBT) Seeking Alpha

IOBT Stock Price and Chart — NASDAQ:IOBT - TradingView

IOBT Stock Price and Chart — NASDAQ:IOBT TradingView

IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines - Fierce Biotech

IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines Fierce Biotech

IO Biotech Inc Stock Price Today | NASDAQ: IOBT Live - Investing.com

IO Biotech Inc Stock Price Today | NASDAQ: IOBT Live Investing.com

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer - Labiotech.eu

Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer Labiotech.eu

Top Io Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant